144 related articles for article (PubMed ID: 6193180)
1. Induction of antigen-specific antibody response in human peripheral blood lymphocytes in vitro by a dog kidney cell vaccine against rabies virus (DKCV).
Uytdehaag FG; Osterhaus AD; Loggen HG; Bakker RH; van Asten JA; Kreeftenberg JG; van der Marel P; van Steenis B
J Immunol; 1983 Sep; 131(3):1234-9. PubMed ID: 6193180
[TBL] [Abstract][Full Text] [Related]
2. Human anti-idiotypic T lymphocyte clones are activated by autologous anti-rabies virus antibodies presented in association with HLA-DQ molecules.
UytdeHaag F; Claassen I; Bunschoten H; Loggen H; Ottenhoff T; Teeuwsen V; Osterhaus A
J Mol Cell Immunol; 1987; 3(3):145-55. PubMed ID: 2908179
[TBL] [Abstract][Full Text] [Related]
3. Human peripheral blood lymphocytes from recently vaccinated individuals produce both type-specific and intertypic cross-reacting neutralizing antibody on in vitro stimulation with one type of poliovirus.
Uytdehaag FG; Loggen HG; Logtenberg T; Lichtveld RA; van Steenis B; van Asten JA; Osterhaus AD
J Immunol; 1985 Nov; 135(5):3094-101. PubMed ID: 2931478
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of human T cell lines and clones reactive to rabies virus: antigen specificity and production of interferon-gamma.
Celis E; Miller RW; Wiktor TJ; Dietzschold B; Koprowski H
J Immunol; 1986 Jan; 136(2):692-7. PubMed ID: 2416820
[TBL] [Abstract][Full Text] [Related]
5. Human peripheral blood mononuclear cells produce IgA anti-influenza virus antibody in a secondary in vitro antibody response.
Yarchoan R; Barrow LA; Kurman C; Strober W; Nelson DL
J Immunol; 1985 Aug; 135(2):1033-9. PubMed ID: 3874224
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte proliferative response to rabies virus antigen.
Melino G; Concato C; Menichella D; Vescia N; Mastroeni I; Pestalozza S; Buonavoglia C; Caliò R
Microbiologica; 1989 Jul; 12(3):215-23. PubMed ID: 2779457
[TBL] [Abstract][Full Text] [Related]
7. A study of the functional capabilities of human neonatal lymphocytes for in vitro specific antibody production.
Yarchoan R; Nelson DL
J Immunol; 1983 Sep; 131(3):1222-8. PubMed ID: 6309961
[TBL] [Abstract][Full Text] [Related]
8. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
9. In vitro influenza virus-specific antibody production in man: antigen-specific and HLA-restricted induction of helper activity mediated by cloned human T lymphocytes.
Lamb JR; Woody JN; Hartzman RJ; Eckels DD
J Immunol; 1982 Oct; 129(4):1465-70. PubMed ID: 6180010
[TBL] [Abstract][Full Text] [Related]
10. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
[TBL] [Abstract][Full Text] [Related]
11. DNA-based immunisation against rabies and rabies-related viruses: towards multivalent vaccines.
Perrin P; Jacob Y; Desmézières E; Tordo N
Dev Biol (Basel); 2000; 104():151-7. PubMed ID: 11713814
[TBL] [Abstract][Full Text] [Related]
12. Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein.
Bunschoten H; Klapmuts RJ; Claassen IJ; Reyneveld SD; Osterhaus AD; Uytdehaag FG
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1513-21. PubMed ID: 2471814
[TBL] [Abstract][Full Text] [Related]
13. In vitro antigen-induced antibody responses to hepatitis B surface antigen in man. Kinetic and cellular requirements.
Cupps TR; Gerin JL; Purcell RH; Goldsmith PK; Fauci AS
J Clin Invest; 1984 Oct; 74(4):1204-13. PubMed ID: 6332826
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine.
Kallel H; Diouani MF; Loukil H; Trabelsi K; Snoussi MA; Majoul S; Rourou S; Dellagi K
Vaccine; 2006 May; 24(22):4856-62. PubMed ID: 16600442
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of antigen-specific human B cells in recently immunized individuals by nonspecific factors in the absence of antigen.
Peters M; Fauci AS
J Immunol; 1983 Feb; 130(2):678-80. PubMed ID: 6184400
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to nucleic acid vaccines to rabies virus.
Xiang ZQ; Spitalnik SL; Cheng J; Erikson J; Wojczyk B; Ertl HC
Virology; 1995 Jun; 209(2):569-79. PubMed ID: 7778289
[TBL] [Abstract][Full Text] [Related]
17. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus.
Lodmell DL; Ewalt LC; Parnell MJ; Rupprecht CE; Hanlon CA
Vaccine; 2006 Jan; 24(4):412-6. PubMed ID: 16153757
[TBL] [Abstract][Full Text] [Related]
18. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies.
Hu RL; Liu Y; Zhang SF; Zhang F; Fooks AR
Vaccine; 2007 Jul; 25(29):5301-7. PubMed ID: 17576027
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to an anti-rabies vaccine in a dog population under field conditions in Bolivia.
Suzuki K; González ET; Ascarrunz G; Loza A; Pérez M; Ruiz G; Rojas L; Mancilla K; Pereira JA; Guzman JA; Pecoraro MR
Zoonoses Public Health; 2008 Oct; 55(8-10):414-20. PubMed ID: 18399941
[TBL] [Abstract][Full Text] [Related]
20. Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions.
Bahloul C; Taieb D; Diouani MF; Ahmed SB; Chtourou Y; B'chir BI; Kharmachi H; Dellagi K
Vaccine; 2006 Feb; 24(8):1063-72. PubMed ID: 16213633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
